
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 18.720 | 18.720 | 0.000 |
Shares | 82.480 | 82.480 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 25.437 | 21.978 |
Price to Book | 3.432 | 3.547 |
Price to Sales | 4.180 | 3.056 |
Price to Cash Flow | 13.924 | 11.512 |
Dividend Yield | 1.119 | 1.632 |
5 Years Earnings Growth | 3.657 | 11.269 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.970 | 27.694 |
Technology | 0.020 | 31.956 |
Number of long holdings: 55
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
BeiGene Ltd Ordinary Shares | - | 8.07 | - | - | |
Innovent Biologics | KYG4818G1010 | 7.51 | 47.75 | +9.27% | |
Jiangsu Hengrui | CNE0000014W7 | 7.05 | 48.38 | -0.25% | |
Shanghai Allist Pharmaceuticals Co | CNE100005XJ7 | 6.37 | 87.45 | +1.97% | |
Sichuan Kelun Biotech | CNE1000062J1 | 4.97 | 302.00 | +7.55% | |
Sichuan Biokin Pharmaceutical | CNE100006FN4 | 4.96 | 244.20 | +1.52% | |
WuXi AppTec | CNE1000031K4 | 4.63 | 52.10 | -0.38% | |
Kelun Pharm A | CNE100000PW7 | 3.89 | 35.68 | +3.27% | |
Sinopep Allsino Bio Pharmaceutical Co | CNE1000051X5 | 3.49 | 50.26 | +0.52% | |
Hutchison China | KYG4672N1198 | 3.23 | 208.00 | +5.85% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CIFM China Emerging Power Class A | 5.34B | 5.66 | -5.79 | 7.93 | ||
CIFM China Emerging Power Class H | 5.34B | 5.66 | -5.82 | - | ||
CIFM Technology Qian Yan Alloc | 2.67B | 2.65 | -6.55 | - | ||
China Intl AsiaPacific Advantage St | 2.43B | 2.62 | 2.96 | 4.96 | ||
China International China Advanced | 1.69B | 6.76 | -4.77 | 4.79 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review